Trial Profile
Single Arm, Exploratory and Open Clinical Trial of Second-line Therapy With Apatinib Mesylate in Advanced Cholangiocarcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 14 May 2018 New trial record